Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals reports interim Phase 1/2a data for ARO-DIMER-PA, demonstrating dual-gene silencing to treat high fat in blood.
Stocks · News reference
Arrowhead Pharmaceuticals Says Phase 1/2a Interim Single-Dose Data For ARO-DIMER-PA Showed Mean Maximal Reductions Of 54% In Bad Cholesterol, 73% In Triglycerides; No Drug-Related Serious Adverse Events
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Arrowhead Pharmaceuticals shares are trading lower. The company announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, RNAi therapeutic dimer for the treatment of mixed hyperlipidemia.
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.